DARE BIOSCIENCE INC. - COMMON STOCK

Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive

11 Apr 2024 08:00:00 By Nasdaq GlobeNewswire

Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update

28 Mar 2024 08:00:00 By Nasdaq GlobeNewswire

Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024

21 Mar 2024 08:00:00 By Nasdaq GlobeNewswire

Daré Bioscience to Present at the International Society for the Study of Women’s Sexual Health (ISSWSH) Annual Meeting

22 Feb 2024 08:00:00 By Nasdaq GlobeNewswire

Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024

31 Jan 2024 08:00:00 By Nasdaq GlobeNewswire

Daré Bioscience Announces Executive Team and Board of Directors Changes

26 Jan 2024 16:30:00 By Nasdaq GlobeNewswire

Daré Bioscience Announces Grant to Support Biotherapeutic Product Development

17 Jan 2024 08:00:00 By Nasdaq GlobeNewswire

Daré Bioscience’s DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women’s Health as well as in Treating a Broad Range of Diseases

04 Jan 2024 08:00:00 By Nasdaq GlobeNewswire

Daré Bioscience Secures $12 million in Royalty-backed Investment Structure

26 Dec 2023 08:00:00 By Nasdaq GlobeNewswire

Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study

20 Dec 2023 08:00:00 By Nasdaq GlobeNewswire

Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-PTB1 Phase 1 Human Clinical Study

13 Dec 2023 08:00:00 By Nasdaq GlobeNewswire

Daré Bioscience Announces FDA Clearance of Investigational New Drug (IND) Application for DARE-VVA1, a Novel Intravaginal Formulation of Tamoxifen for Moderate to Severe Dyspareunia, a Symptom of Vulvar and Vaginal Atrophy Associated with Menopause

07 Dec 2023 08:00:00 By Nasdaq GlobeNewswire

Daré Bioscience Announces Commencement of Phase 3 Study of Ovaprene®, an Investigational Hormone-Free Monthly Intravaginal Contraceptive

04 Dec 2023 08:00:00 By Nasdaq GlobeNewswire

Daré Bioscience and Premier Research Extend Strategic Partnership to Accelerate the Clinical Development of Daré’s Novel Women’s Health Programs

20 Nov 2023 08:00:00 By Nasdaq GlobeNewswire

Daré Bioscience to Present at the Sexual Medicine Society of North America (SMSNA) 24th Annual Fall Scientific Meeting

13 Nov 2023 08:00:00 By Nasdaq GlobeNewswire

Daré Bioscience Reports Third Quarter 2023 Financial Results and Provides Company Update

09 Nov 2023 08:00:00 By Nasdaq GlobeNewswire

Daré Bioscience to Participate in Three November Conferences

06 Nov 2023 08:00:00 By Nasdaq GlobeNewswire

Daré Bioscience to Host Third Quarter 2023 Financial Results and Company Update Conference Call and Webcast on November 9, 2023

02 Nov 2023 08:00:00 By Nasdaq GlobeNewswire

Daré Bioscience Announces Additional Positive Data from Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women and Proposed Endpoints and Patient Population for Phase 3 Program

01 Nov 2023 08:00:01 By Nasdaq GlobeNewswire

Daré Bioscience Announces Achievement of First Commercial Milestone Under License Agreement for XACIATO™ (Clindamycin Phosphate) Vaginal Gel, 2%, FDA-Approved Treatment for Bacterial Vaginosis in Females 12 Years or Older

16 Oct 2023 08:00:01 By Nasdaq GlobeNewswire